NB

Nigel R. A. Beeley

ET Elcelyx Therapeutics: 13 patents #1 of 5Top 20%
AP Amylin Pharmaceuticals: 4 patents #32 of 151Top 25%
AP Anji Pharmaceuticals: 2 patents #3 of 8Top 40%
AL Astrazeneca Pharmaceuticals Lp: 1 patents #40 of 76Top 55%
📍 Solana Beach, CA: #34 of 500 inventorsTop 7%
🗺 California: #23,010 of 386,348 inventorsTop 6%
Overall (All Time): #169,586 of 4,157,543Top 5%
24
Patents All Time

Issued Patents All Time

Showing 1–24 of 24 patents

Patent #TitleCo-InventorsDate
11974971 Compositions and methods for treating metabolic disorders Alain D. Baron, Mark S. Fineman 2024-05-07
11865113 Methods of treating a patient afflicted with non-alcoholic steatohepatitis (NASH) J. Gordon Foulkes, Kieran George Mooney, Charles Rodney Greenaway Evans, Keith Johnson, Howard Welgus +1 more 2024-01-09
11759441 Biguanide compositions and methods of treating metabolic disorders Alain D. Baron, Mark S. Fineman 2023-09-19
11065215 Biguanide compositions and methods of treating metabolic disorders Alain D. Baron, Mark S. Fineman 2021-07-20
10668031 Biguanide compositions and methods of treating metabolic disorders Alain D. Baron, Mark S. Fineman 2020-06-02
10610500 Chemosensory receptor ligand-based therapies Alain D. Baron, Mark S. Fineman 2020-04-07
10603291 Compositions and methods for treating metabolic disorders Alain D. Baron, Mark S. Fineman 2020-03-31
10201511 Compositions and methods for treating metabolic disorders Alain D. Baron, Mark S. Fineman 2019-02-12
10159658 Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk Alain D. Baron, Mark S. Fineman 2018-12-25
10154972 Biguanide compositions and methods of treating metabolic disorders Alain D. Baron, Mark S. Fineman 2018-12-18
10028923 Biguanide compositions and methods of treating metabolic disorders Alain D. Baron, Mark S. Fineman 2018-07-24
9962344 Chemosensory receptor ligand-based therapies Alain D. Baron, Mark S. Fineman 2018-05-08
9770422 Compositions and methods for treating metabolic disorders Alain D. Baron, Mark S. Fineman 2017-09-26
9572784 Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk Alain D. Baron, Mark S. Fineman 2017-02-21
9480663 Biguanide compositions and methods of treating metabolic disorders Alain D. Baron, Mark S. Fineman 2016-11-01
9481642 Biguanide compositions and methods of treating metabolic disorders Alain D. Baron, Mark S. Fineman 2016-11-01
9463170 Chemosensory receptor ligand-based therapies Alain D. Baron, Mark S. Fineman 2016-10-11
9211263 Compositions and methods of treating metabolic disorders Alain D. Baron, Mark S. Fineman 2015-12-15
9050292 Chemosensory receptor ligand-based therapies Alain D. Baron, Martin R. Brown, Christopher R. G. Jones, Mark S. Fineman 2015-06-09
8796338 Biguanide compositions and methods of treating metabolic disorders Alain D. Baron, Mark S. Fineman 2014-08-05
8759291 Methods of treatment using exendin peptides or GLP-1 peptides Andrew A. Young, Will Vine, Kathryn S. Prickett 2014-06-24
7928065 Methods of treatment using exendin peptides or GLP-1 peptides Andrew A. Young, Will Vine, Kathryn S. Prickett 2011-04-19
7442680 Inotropic and diuretic effects of GLP-1 and GLP-1 agonists Andrew A. Young, Will Vine, Kathryn S. Prickett 2008-10-28
6703359 Inotropic and diuretic effects of exendin and GLP-1 Andrew A. Young, Will Vine, Kathryn S. Prickett 2004-03-09